Kids & teens (for parents) · Minnesota
Studies for children and teens in Minnesota
These studies only enroll people under 18. A parent or legal guardian gives permission, and children old enough to understand are asked for their own agreement (assent).
35 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 3
Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents
Pfizer
- Location
- Minneapolis, MN + 49 other US sites
- Eligibility basics
- Ages 1–17
- RecruitingHealthy volunteersPhase 3
A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age
GlaxoSmithKline
- Location
- Mankato, MN + 14 other US sites
- Eligibility basics
- Ages 1–1
- RecruitingHealthy volunteers
Parent-Child EF Intervention
Koronis Biomedical Technologies
- Location
- Minneapolis, MN
- Eligibility basics
- Ages 2–5
- RecruitingPhase 1/Phase 2
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
Encoded Therapeutics
- Location
- Rochester, MN + 9 other US sites
- Eligibility basics
- Ages 6 mo–17
- RecruitingPhase 3
A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
Amicus Therapeutics
- Location
- Minneapolis, MN + 5 other US sites
- Eligibility basics
- Ages 2–11
- RecruitingPhase 2/Phase 3
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
Bristol-Myers Squibb
- Location
- Rochester, MN + 11 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
AbbVie
- Location
- Minneapolis, MN + 9 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
Lumos Pharma
- Location
- Minneapolis, MN + 30 other US sites
- Eligibility basics
- Ages 3–11
- RecruitingPhase 2/Phase 3
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
Crinetics Pharmaceuticals Inc.
- Location
- Minneapolis, MN + 9 other US sites
- Eligibility basics
- Ages 1–17
- RecruitingPhase 3
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
Sanofi
- Location
- Eagan, MN + 14 other US sites
- Eligibility basics
- Ages 6 mo–17
- RecruitingPhase 1
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
Merck Sharp & Dohme LLC
- Location
- Minneapolis, MN + 20 other US sites
- Eligibility basics
- Up to age 17
- RecruitingPhase 3
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
AstraZeneca
- Location
- Saint Paul, MN + 18 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
Ascendis Pharma A/S
- Location
- Minneapolis, MN + 21 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 1
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
Pfizer
- Location
- Minneapolis, MN + 10 other US sites
- Eligibility basics
- Ages 6–11
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
Janssen Research & Development, LLC
- Location
- Rochester, MN + 9 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Pfizer
- Location
- Rochester, MN + 69 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old
Neurocrine Switzerland GmbH
- Location
- Minneapolis, MN + 10 other US sites
- Eligibility basics
- Ages 4 mo–3
- RecruitingPhase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie
- Location
- Burnsville, MN + 87 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)
Takeda
- Location
- Minneapolis, MN + 9 other US sites
- Eligibility basics
- Up to age 17
- RecruitingPhase 3
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Eli Lilly and Company
- Location
- Minneapolis, MN + 28 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 1/Phase 2
ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
Ionis Pharmaceuticals, Inc.
- Location
- Rochester, MN + 4 other US sites
- Eligibility basics
- Ages 2–12
- RecruitingPhase 3
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
AbbVie
- Location
- Minneapolis, MN + 11 other US sites
- Eligibility basics
- Ages 5–17
- Recruiting
Establishing the Preliminary Utility of a Novel Pediatric Manual Mobile Standing Wheelchair
Optimal Mobility, Inc
- Location
- Saint Paul, MN
- Eligibility basics
- Ages 8–17
- RecruitingPhase 2
A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature
BioMarin Pharmaceutical
- Location
- Minneapolis, MN + 30 other US sites
- Eligibility basics
- Ages 3–11